Post-immunotherapy imaging in lung cancer

G. S. Shroff; C. D. Strange; M. Altan; B. W. Carter; J. Ahuja; M. C.B. Godoy; M. T. Truong; I. Vlahos

doi:10.1016/j.crad.2021.05.003

Post-immunotherapy imaging in lung cancer

G. S. Shroff, C. D. Strange, M. Altan, B. W. Carter, J. Ahuja, M. C.B. Godoy, M. T. Truong, I. Vlahos

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

By boosting the immune system, immunotherapy with immune checkpoint inhibitors (ICIs) has altered the management of patients with various cancers including those with metastatic non-small cell lung cancer (NSCLC). As a result of immune system activation, ICIs are associated with unique response patterns (that are not addressed by traditional response criteria) and inflammatory side effects termed immune-related adverse events. In this article, we will review the role of immunotherapy in cancer treatment, specifically ICIs used in NSCLC treatment, radiological response criteria of immunotherapy, and the imaging spectrum of immune-related adverse events.

Original language	English (US)
Pages (from-to)	44-57
Number of pages	14
Journal	Clinical Radiology
Volume	77
Issue number	1
DOIs	https://doi.org/10.1016/j.crad.2021.05.003
State	Published - Jan 2022

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.crad.2021.05.003

Cite this

@article{4f4d7b92c87d4d8e8b89495d003c6a34,

title = "Post-immunotherapy imaging in lung cancer",

abstract = "By boosting the immune system, immunotherapy with immune checkpoint inhibitors (ICIs) has altered the management of patients with various cancers including those with metastatic non-small cell lung cancer (NSCLC). As a result of immune system activation, ICIs are associated with unique response patterns (that are not addressed by traditional response criteria) and inflammatory side effects termed immune-related adverse events. In this article, we will review the role of immunotherapy in cancer treatment, specifically ICIs used in NSCLC treatment, radiological response criteria of immunotherapy, and the imaging spectrum of immune-related adverse events.",

author = "Shroff, {G. S.} and Strange, {C. D.} and M. Altan and Carter, {B. W.} and J. Ahuja and Godoy, {M. C.B.} and Truong, {M. T.} and I. Vlahos",

note = "Publisher Copyright: {\textcopyright} 2021 The Royal College of Radiologists",

year = "2022",

month = jan,

doi = "10.1016/j.crad.2021.05.003",

language = "English (US)",

volume = "77",

pages = "44--57",

journal = "Clinical Radiology",

issn = "0009-9260",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Post-immunotherapy imaging in lung cancer

AU - Shroff, G. S.

AU - Strange, C. D.

AU - Altan, M.

AU - Carter, B. W.

AU - Ahuja, J.

AU - Godoy, M. C.B.

AU - Truong, M. T.

AU - Vlahos, I.

PY - 2022/1

Y1 - 2022/1

N2 - By boosting the immune system, immunotherapy with immune checkpoint inhibitors (ICIs) has altered the management of patients with various cancers including those with metastatic non-small cell lung cancer (NSCLC). As a result of immune system activation, ICIs are associated with unique response patterns (that are not addressed by traditional response criteria) and inflammatory side effects termed immune-related adverse events. In this article, we will review the role of immunotherapy in cancer treatment, specifically ICIs used in NSCLC treatment, radiological response criteria of immunotherapy, and the imaging spectrum of immune-related adverse events.

AB - By boosting the immune system, immunotherapy with immune checkpoint inhibitors (ICIs) has altered the management of patients with various cancers including those with metastatic non-small cell lung cancer (NSCLC). As a result of immune system activation, ICIs are associated with unique response patterns (that are not addressed by traditional response criteria) and inflammatory side effects termed immune-related adverse events. In this article, we will review the role of immunotherapy in cancer treatment, specifically ICIs used in NSCLC treatment, radiological response criteria of immunotherapy, and the imaging spectrum of immune-related adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85107349906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107349906&partnerID=8YFLogxK

U2 - 10.1016/j.crad.2021.05.003

DO - 10.1016/j.crad.2021.05.003

M3 - Review article

C2 - 34103147

AN - SCOPUS:85107349906

SN - 0009-9260

VL - 77

SP - 44

EP - 57

JO - Clinical Radiology

JF - Clinical Radiology

IS - 1

ER -

Post-immunotherapy imaging in lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this